Medy-Tox Inc. (KOSDAQ:086900)
South Korea · Delayed Price · Currency is KRW 99,200
-300 (-0.30%)
Apr 3, 2026, 3:30 PM KST
Medy-Tox Revenue
In the year 2025, Medy-Tox had annual revenue of 247.29B KRW with 8.17% growth. Medy-Tox had revenue of 60.67B in the quarter ending December 31, 2025, with 9.96% growth.
Revenue
247.29B
Revenue Growth
+8.17%
P/S Ratio
2.63
Revenue / Employee
344.42M
Employees
718
Market Cap
650.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.29B | 18.67B | 8.17% |
| Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
| Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
| Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
| Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.45T |
| BINEX | 168.47B |
| MEDIPOST | 73.66B |
| Onconic Therapeutics | 53.39B |
| Pharmicell | 23.94B |
| SillaJen | 9.23B |
| Anterogen.Co.,Ltd. | 7.54B |
| GI Innovation | 5.84B |